Mexico Androgenetic Alopecia Market Size & Outlook
Mexico androgenetic alopecia market, 2018-2030 (US$M)
Related Markets
Mexico androgenetic alopecia market highlights
- The Mexico androgenetic alopecia market generated a revenue of USD 13.0 million in 2023 and is expected to reach USD 24.2 million by 2030.
- The Mexico market is expected to grow at a CAGR of 9.3% from 2024 to 2030.
- In terms of segment, pharmaceuticals was the largest revenue generating treatment in 2023.
- Devices is the most lucrative treatment segment registering the fastest growth during the forecast period.
Androgenetic alopecia market data book summary
| Market revenue in 2023 | USD 13.0 million |
| Market revenue in 2030 | USD 24.2 million |
| Growth rate | 9.3% (CAGR from 2023 to 2030) |
| Largest segment | Pharmaceuticals |
| Fastest growing segment | Devices |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pharmaceuticals, Devices |
| Key market players worldwide | Johnson & Johnson, Cipla Ltd DR, Sun Pharmaceutical Industries, Merck & Co Inc, Dr. Reddy’s Laboratories, Cardiff Lexington Corp, Amgen Inc, Theradome, Aurobindo Pharma, Curallux, Apira Science |
Other key industry trends
- In terms of revenue, Mexico accounted for 0.5% of the global androgenetic alopecia market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil androgenetic alopecia market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 24.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Androgenetic Alopecia Market Scope
Androgenetic Alopecia Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico androgenetic alopecia market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to androgenetic alopecia market will help companies and investors design strategic landscapes.
Pharmaceuticals was the largest segment with a revenue share of 98.46% in 2023. Horizon Databook has segmented the Mexico androgenetic alopecia market based on pharmaceuticals, devices covering the revenue growth of each sub-segment from 2018 to 2030.
The androgenetic alopecia market in Mexico is expected to exhibit a significant growth rate over the forecast period. Mexico’s proximity to the U.S. is expected to create major opportunities as it provides access to modern healthcare tools, technologies, and human resources.
Moreover, the geriatric population in Mexico accounts for 7% of its total population, slightly lower than Argentina’s 11% and Brazil’s 9%. However, the overall population in Mexico is nearly three times that of Argentina, which makes it one of the lucrative markets for AGA treatment in Latin America.
The increasing healthcare expenditure of the country may bridge the infrastructure gap. In 2020, the per capita healthcare expenditure was USD 538.57, and it is expected to increase in the coming decade. The major share of AGA treatment was reported for minoxidil, which was 26.5%, followed by 5- ARI medications, such as Alpha-Estradiol (topical) at 10.7% and Finasteride with 10.2%.
Reasons to subscribe to Mexico androgenetic alopecia market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Mexico androgenetic alopecia market databook
-
Our clientele includes a mix of androgenetic alopecia market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico androgenetic alopecia market , including forecasts for subscribers. This country databook contains high-level insights into Mexico androgenetic alopecia market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Mexico androgenetic alopecia market size, by treatment, 2018-2030 (US$M)
Mexico Androgenetic Alopecia Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
